These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37533677)

  • 21. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
    Hiroki H; Akahane K; Inukai T; Morio T; Takagi M
    Int J Hematol; 2023 May; 117(5):748-758. PubMed ID: 36575328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PARP inhibitors - A better selection of patients].
    Senglet M; Berthod G; Courtes MG; Anchisi S; Membrez V; Nay Fellay C
    Rev Med Suisse; 2023 May; 19(827):932-937. PubMed ID: 37195105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unifying targeted therapy for leukemia in the era of PARP inhibition.
    Boila LD; Sengupta A
    Exp Hematol; 2023 Aug; 124():1-14. PubMed ID: 37236341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to PARP-Inhibitors in Cancer Therapy.
    Montoni A; Robu M; Pouliot E; Shah GM
    Front Pharmacol; 2013; 4():18. PubMed ID: 23450678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
    Martincuks A; Song J; Kohut A; Zhang C; Li YJ; Zhao Q; Mak E; Rodriguez-Rodriguez L; Yu H; Cristea M
    Front Oncol; 2021; 11():724104. PubMed ID: 34956861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.
    Caracciolo D; Scionti F; Juli G; Altomare E; Golino G; Todoerti K; Grillone K; Riillo C; Arbitrio M; Iannone M; Morelli E; Amodio N; Di Martino MT; Rossi M; Neri A; Tagliaferri P; Tassone P
    Haematologica; 2021 Jan; 106(1):185-195. PubMed ID: 32079692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
    Bellio C; DiGloria C; Foster R; James K; Konstantinopoulos PA; Growdon WB; Rueda BR
    Mol Cancer Res; 2019 Feb; 17(2):431-445. PubMed ID: 30401718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
    Alhusaini A; Cannon A; Maher SG; Reynolds JV; Lynam-Lennon N
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of poly (ADP-Ribose) polymerase-1 in telomerase deficient mouse embryonic fibroblasts increases arsenite-induced genome instability.
    Gurung RL; Balakrishnan L; Bhattacharjee RN; Manikandan J; Swaminathan S; Hande MP
    Genome Integr; 2010 May; 1(1):5. PubMed ID: 20678253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
    Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells.
    Hirai T; Saito S; Fujimori H; Matsushita K; Nishio T; Okayasu R; Masutani M
    Biochem Biophys Res Commun; 2016 Sep; 478(1):234-240. PubMed ID: 27425251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    Perez JM; Twigg CAI; Guan W; Thomas SN
    J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
    Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
    Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
    Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
    Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
    Jannetti SA; Carlucci G; Carney B; Kossatz S; Shenker L; Carter LM; Salinas B; Brand C; Sadique A; Donabedian PL; Cunanan KM; Gönen M; Ponomarev V; Zeglis BM; Souweidane MM; Lewis JS; Weber WA; Humm JL; Reiner T
    J Nucl Med; 2018 Aug; 59(8):1225-1233. PubMed ID: 29572254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP Inhibitors for Breast Cancer: Germline
    Menezes MCS; Raheem F; Mina L; Ernst B; Batalini F
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.